Oniria Therapeutics, VHIO and VHIR awarded €964,000 from the Spanish Ministry of Science and Innovation and EU to develop a TET2 drug activator for the treatment of melanoma

Oniria Therapeutics received €964,000 from the Ministry of Science, Innovation and Universities of Spain and European Union, through the Next Generation EU program, for a public-private collaboration project entitled Develop a TET2 drug activator for the treatment of melanoma.

TET2, a master epigenetic enzyme, is the Achilles heel of persistent tumour cells, and Oniria’s new drugs focus on attacking this vulnerability.

The project will be carried out in collaboration with the Dr. Hector G Palmer’s Lab at Vall d’Hebron Institute of Oncology (VHIO) and Dr. Juan Angel Recio’s Lab at Vall d’Hebron Institute of Research (VHIR) between 2024 to 2026.